Medicine & Health

Researchers at WashU Medicine conducted a study to understand the genetic factors behind a pediatric brain tumor. Their findings could lead to new targeted therapies.

A new analysis, led by WashU Medicine researchers and published in Cell Genomics, examines how certain proteins in human cells are implicated in both cancer and neurodevelopmental disorders, but behave differently, complicating potential interventions.

An international clinical trial co-led by WashU Medicine found that the immunotherapy drug pembrolizumab added to standard-of-care therapy improved survival for patients with locally advanced head and neck cancer. Pembrolizumab helps the patient’s own immune cells attack and kill tumor cells.

A new study led by WashU Medicine researchers takes a deep dive into inherited genetic mutations. The findings have implications for determining an individual’s inherited cancer risk and informing potential new strategies for prevention, early detection and treatment.

Researchers at WashU Medicine described, in mice, a brain pathway that connects the loss of motivation characteristic of advanced cancer to cancer-related inflammation and identified opportunities to block this pathway and restore motivation.

Researchers at Washington University have developed a method to peer into biomolecular condensates, which could lead to a better understanding of condensate functions and their impairment in cancers and neurodegeneration.

Graham A. Colditz, MD, DrPH, the Niess-Gain Professor of Surgery and director of the Public Health Sciences Division in the Department of Surgery at WashU Medicine, has been awarded the Brinker Award for Scientific Distinction in Population Science.

The National Cancer Institute, part of the National Institutes of Health (NIH), has awarded Aimilia Gastounioti, an assistant professor at WashU Medicine, a five-year $3 million grant to improve breast cancer risk assessments for Black women.

Research from WashU Medicine found a possible new treatment strategy for certain types of blood cancers.

A phase 1 clinical trial co-led by researchers at WashU Medicine found that a new type of cell-based immunotherapy was safe for patients with several types of B-cell lymphoma, a type of blood cancer.